| Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing S Durdagi, Ç Dağ, B Dogan, M Yigin, T Avsar, C Buyukdag, I Erol, ... Structure 29 (12), 1382-1396. e6, 2021 | 29 | 2021 |
| The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies S Durdagi, T Avsar, MD Orhan, M Serhatli, BK Balcioglu, HU Ozturk, ... Molecular Therapy 30 (2), 963-974, 2022 | 24 | 2022 |
| Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance … G Tutumlu, B Dogan, T Avsar, MD Orhan, S Calis, S Durdagi Frontiers in Chemistry 8, 167, 2020 | 24 | 2020 |
| Genome-wide identification of Chiari malformation type I associated candidate genes and chromosomal variations T AvŞar, Ş Çaliş, B Yilmaz, GD Otluoğlu, C Holyavkin, T KiliÇ Turkish Journal of Biology 44 (6), 449-456, 2020 | 12 | 2020 |
| A novel BH3 mimetic Bcl-2 inhibitor promotes autophagic cell death and reduces in vivo Glioblastoma tumor growth S Calis, B Dogan, S Durdagi, A Celebi, O Yapicier, T Kilic, ET Turanli, ... Cell Death Discovery 8 (1), 433, 2022 | 10 | 2022 |
| Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS‐CoV‐2: A Combined in silico and in vitro Study S Durdagi, MD Orhan, B Aksoydan, S Calis, B Dogan, K Sahin, ... Molecular Informatics 41 (2), 2100062, 2022 | 9 | 2022 |
| Near-physiological-temperature serial femtosecond X-ray crystallography reveals novel conformations of SARS-CoV-2 main protease active site for improved drug repurposing S Durdagi, C Dag, B Dogan, M Yigin, T Avsar, C Buyukdag, I Erol, B Ertem, ... bioRxiv, 2020.09. 09.287987, 2020 | 4 | 2020 |
| Synthesis, Characterization, Biological Activity and Molecular Modeling Studies of Novel Aminoguanidine Derivatives N Doğan, SÇ Yavuz, K Sahin, MD Orhan, H Kekeçmuhammed, S Calis, ... ChemistrySelect 7 (45), e202202819, 2022 | 3 | 2022 |
| Development of imidazolone based angiotensin II receptor type I inhibitor small molecule as a chemotherapeutic agent for cell cycle inhibition T Avsar, BN Yigit, G Turan, D Altunsu, S Calis, B Kurt, T Kilic, ... All Life 14 (1), 678-690, 2021 | 3 | 2021 |
| Association of MTHFR, MTRR and RAD54L Gene Variations with Meningioma and Correlation with Tumor’s Histopathological Characteristics on Turkish Cohort T Avsar, R Mohiyuddin, S Calis, O Yapicier, T Kilic Turk Neurosurg 31 (4), 587-593, 2021 | 3 | 2021 |
| Lomeguatrib, a O6-Methylguanine-DNA-methyltransferase (MGMT) inhibitor, induces DNA damage induced apoptosis by targeting double-strand DNA repair in multiple myeloma DA Yildiz, T Ozkan, Y Yukselten, NT Sesli, S Ozkanca, M Gunduz, M Ozen, ... Blood 128 (22), 2103, 2016 | 1 | 2016 |
| PRKCA, PTPN1 and ZYX Are Possible Markers to Target CD133+ GBM Stem Cells S Ozkanca, MG Bal, Y Yukselten, DA Yildiz, HC Ugur, K Demircan, ... The FASEB Journal 30, lb442-lb442, 2016 | 1 | 2016 |
| PXN and TRIO are elevated in CD133+ GSCs transcriptomically A Sunguroglu, M Bunsuz, Y Yukselten, MG Bal, S Ozkanca, DA Yildiz, ... The FASEB Journal 30, lb96-lb96, 2016 | 1 | 2016 |
| Abstract LB021: BAU-243: A novel BCL-2 inhibitor inducing autophagic cell death in glioblastoma, unveiled through multistep virtual screening, comprehensive in vitro and in … S Calis, B Dogan, A Celebi, O Yapicier, T Kilic, ET Turanli, T Avsar, ... Cancer Research 84 (7_Supplement), LB021-LB021, 2024 | | 2024 |
| 492 Novel BH3 Mimetic Bcl-2 Inhibitor Promotes Autophagic Cell Death and Reduces in Vivo Glioblastoma Tumor Growth T Avsar, S Calis, T Kilic Neurosurgery 70 (Supplement_1), 150-151, 2024 | | 2024 |
| Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells D Akcora‐Yildiz, T Ozkan, B Cetintav, Y Yukselten, S Calis, ... Chemical Biology & Drug Design 103 (2), e14465, 2024 | | 2024 |
| Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor S Durdagi, T Avsar, MD Orhan, G Cacan, B Dogan, S Calis US Patent App. 17/929,007, 2023 | | 2023 |
| Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor MD Orhan, S Durdagi, B Dogan, S Calis, G Cacan, T Avsar US Patent App. 17/929,003, 2023 | | 2023 |
| Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor MD Orhan, B Dogan, S Calis, G Cacan, T Avsar, S Durdagi US Patent App. 17/929,002, 2023 | | 2023 |
| Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor B Dogan, S Durdagi, G Cacan, S Calis, T Avsar, MD Orhan US Patent App. 17/760,464, 2023 | | 2023 |
Timucin AvsarBahcesehir University, School of Medicinebau.edu.tr üzerinde doğrulanmış e-posta adresine sahip
